Advertisement

Fall 37: Prävention – 47 Jahre, ♂, Prädiabetes, familiär gehäufte Schlaganfälle

  • Lars Kihm
Chapter

Zusammenfassung

Ein 47-jähriger Patient mit gestörter Glukosetoleranz, einem BMI von 35, einem Blutdruck ohne ausreichende nächtliche Absenkung von tags 145/95 mm Hg, einem LDL von 150 mg/dl und familiärer Häufung von Schlaganfällen kommt nach dem frühen Tod seines Vaters zur Beratung. Für welche Maßnahmen gibt es Evidenzen?

Literatur

  1. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Z, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT, Group ESCSD (2016) 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37(39):2999–3058.  https://doi.org/10.1093/eurheartj/ehw272CrossRefGoogle Scholar
  2. Colhoun HM et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364(9435):685–696CrossRefGoogle Scholar
  3. Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, Gomez-Gracia E, Ruiz-Gutierrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pinto X, Basora J, Munoz MA, Sorli JV, Martinez JA, Martinez-Gonzalez MA, Investigators PS (2013) Primary prevention of cardiovascular disease with a Mediterranean diet. New Engl J Med 368(14):1279–1290.  https://doi.org/10.1056/NEJMoa1200303CrossRefPubMedGoogle Scholar
  4. Lonn EM, Bosch J, Lopez-Jaramillo P, Zhu J, Liu L, Pais P, Diaz R, Xavier D, Sliwa K, Dans A, Avezum A, Piegas LS, Keltai K, Keltai M, Chazova I, Peters RJ, Held C, Yusoff K, Lewis BS, Jansky P, Parkhomenko A, Khunti K, Toff WD, Reid CM, Varigos J, Leiter LA, Molina DI, McKelvie R, Pogue J, Wilkinson J, Jung H, Dagenais G, Yusuf S, Investigators H (2016) Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. New Engl J Med 374(21):2009–2020.  https://doi.org/10.1056/NEJMoa1600175CrossRefPubMedGoogle Scholar
  5. Look AHEAD Research Group. Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Harrison B, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montez MG, Murillo A, Nathan DM, Patricio J, Peters A, Pi-Sunyer X, Pownall H, Reboussin D, Regensteiner JG, Rickman AD, Ryan DH, Safford M, Wadden TA, Wagenknecht LE, West DS, Williamson DF, Yanovski SZ (2013) Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 369(2):145–154CrossRefGoogle Scholar
  6. The ACCORD Study Group; Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. New Engl J Med 362(17):1575–1585.  https://doi.org/10.1056/NEJMoa1001286CrossRefGoogle Scholar
  7. The SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT (2015) A randomized trial of intensive versus standard blood-pressure control. New Engl J Med 373(22):2103–2116.  https://doi.org/10.1056/NEJMoa1511939CrossRefGoogle Scholar
  8. Verterans Administration Cooperative Study Group on Antihypertensive Agents (1967) Effects of treatment on morbidity in hypertension. results in patients with diastolic blood pressures averaging 115 through 129 mm Hg (1967). JAMA 202(11):1028–1034CrossRefGoogle Scholar
  9. Verterans Administration Cooperative Study Group on Antihypertensive Agents (1970) Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg (1970). JAMA 213(7):1143–1152CrossRefGoogle Scholar
  10. Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, Pais P, Lopez-Jaramillo P, Leiter LA, Dans A, Avezum A, Piegas LS, Parkhomenko A, Keltai K, Keltai M, Sliwa K, Peters RJ, Held C, Chazova I, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Sanchez-Vallejo G, McKelvie R, Pogue J, Jung H, Gao P, Diaz R, Lonn E, Investigators H- (2016) Cholesterol lowering in intermediate-risk persons without cardiovascular disease. New Engl J Med 374(21):2021–2031.  https://doi.org/10.1056/NEJMoa1600176CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Abteilung Innere Medizin IMedizinische UniversitätsklinikHeidelbergDeutschland

Personalised recommendations